SVRASavara Inc
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$123M
- 20% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$42M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired56× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$41M | −$39M | −$60M | −$103M | −$124M | 20% |
| Net income | −$43M | −$38M | −$55M | −$96M | −$119M | 24% |
| Operating cash flow | −$40M | −$35M | −$51M | −$89M | −$101M | 13% |
| Capex | $57K | $9K | $296K | $25K | $22K | 12% |
| Stock-based comp | $3M | $2M | $4M | $10M | $14M | 46% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $10M | 196 | — |
| FY2024 | $5M | $4M | 65 | — |
| FY2023 | $4M | $6M | 303 | — |